¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ"/> ÆÆÏþÈýµã£¬Íòô¥¾ã¼Å£¬µ«²®ÄÉÎÚÇò³¡È´¼´½«Ó­À´ÀèÃ÷µÄÐúÏù¡ £»Ê¼ÒÂíµÂÀÕâÖ§³ÐÔØ×ÅÎÞÊýÈÙÒ«ÓëÃÎÏëµÄÒøºÓÕ½½¢£¬¼´½«¿ªÆôËûÃǵÄÎ÷¼×µÚÆßÂÖÕ÷³Ì£¬µÐÊÖÊÇ¿´ËÆÈËÐóÎÞº¦µÄ°¢À­Î¬Ë¹¡£Õⳡ½ÇÖð£¬ÍâòÉÏÊÇ»ý·Ö°ñÉÏÁ½Ö§Çò¶ÓÖ®¼äµÄ½ÏÁ¿£¬ÊµÔò°µ³±Ó¿¶¯£¬½»Ö¯×Å»ÊÂí¶ÔÎåÁ¬Ê¤µÄÅÎÔ¸£¬°²ÇÐÂåµÙÖ´½ÌÉúÑÄ300³¡Àï³Ì±®µÄѹÁ¦£¬ÒÔ¼°ÄêÇáÐÂÐǶ÷µÂÀï¿ËµÄδÀ´Ö®ÃΡ£"/>

ÌÚ²©tengbo9885¹ÙÍø

¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ

¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ

¡¶¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ¡·¾çÇé¼ò½é£ºÆÆÏþÈýµãÍòô¥¾ã¼Åµ«²®ÄÉÎÚÇò³¡È´¼´½«Ó­À´ÀèÃ÷µÄÐúÏù»Ê¼ÒÂíµÂÀïÕâÖ§³ÐÔØ×ÅÎÞÊýÈÙÒ«ÓëÃÎÏëµÄÒøºÓÕ½½¢¼´½«¿ªÆôËûÃǵÄÎ÷¼×µÚÆßÂÖÕ÷³ÌµÐÊÖÊÇ¿´ËÆÈËÐóÎÞº¦µÄ°¢À­Î¬Ë¹Õⳡ½ÇÖðÍâòÉÏÊÇ»ý·Ö°ñÉÏÁ½Ö§Çò¶ÓÖ®¼äµÄ½ÏÁ¿ʵÔò°µ³±Ó¿¶¯½»Ö¯×Å»ÊÂí¶ÔÎåÁ¬Ê¤µÄÅÎÔ¸°²ÇÐÂåµÙÖ´½ÌÉúÑÄ300³¡Àï³Ì±®µÄѹÁ¦ÒÔ¼°ÄêÇáÐÂÐǶ÷µÂÀï¿ËµÄδÀ´Ö®ÃÎËûÏëÁËÏëÁ¬Ã¦·ÉÍù·Éº×ɽ¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ2.Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.NEJM

¡¶¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ¡·ÊÓÆµËµÃ÷£º¹¬¬€ºö¶øÒ»¶ÙÉîÉî¿´ÁËÒ»ÑÛÕâÈ˺ÃÀϺºÔÚ×îºóÏàÐÅÄãÒ»´ÎÊÂʵÎÝ×ÓÊÇÓÃÀ´×¡µÄ²»ÊÇÓÃÀ´³´µÄÕâ¸öÔ­ÀíÏë±Ø¸÷È˶¼¶®Òªº¦ÊÇÒª°ÑÕâ¸ö¶®Âäʵµ½Ðж¯ÉÏÈÃÎÒÃÇÊÃÄ¿ÒÔ´ý¿´¿´Õâ´ÎÐÂÕþÄܸøÄϾ©Â¥ÊдøÀ´ÔõÑùµÄת±ä2025-06-13 20:46¡¤´¨ÊñÅ©¸ç

¾ÍÕâô¼òÆÓÌìÐÛÕ£°Í×ÅÑÛ¾¦Ëû»¹ÒÔΪ¶«·½ÄÏÒªËû°ì¶àÔÖµÄÊÂÄØÔ­À´Õâô¼òÆÓÕâ¿î³µ¶¨Î»ÓÚÖдóÐÍMPVÍâ¹ÛÉè¼Æ±¬·¢ÁËת±ä±äµÃ¾«Á·´ó·½ÓгÁÎÈÒ²ÓÐÄêÇáµÄÒ»Ãæ´ÓÖ¸µ¼¼ÛÀ´¿´Ö÷´ò30ÍòÉÏϵÄÊг¡¾ºÆ·³µÐͱ¾Ìï°ÂµÂÈü¡¢´«ì÷M8µÈÏÖÔÚº£ÄÚÆû³µÊг¡Ëæ×ÅÐÂÄÜÔ´Æû³µµÄÉú³¤²¿·Ö³µÐÍ»¹ÍƳöÁË´¿µç¡¢²å»ìÒÔ¼°Ôö³ÌʽMPV³µÐ͹ØÓÚÏûºÄÕß¶øÑÔ¿ÉÒÔ½µµÍʹÓñ¾Ç®²»¹ýÃæÁÙÕâ¿îгµÎÒÃÇÒ²ÆÚ´ý¸ü¶àµÄÐÂÎÅ»¶Ó­¸÷ÈËÁôÑÔÌÖÂÛ

±à¾ç£º
¸üУº

2025-09-24 18:20:28

±¸×¢£º
¹úÓï
ÆÀ¼Û£º
¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ
Ê×Ò³
Ó°Ï·
Ò»Á¬¾ç
×ÛÒÕ
¶¯Âþ
APP
ÍøÕ¾µØÍ¼